| International Therapy Solutions, Pllc | |
|
11480 E. 13 Mile Rd Warren MI 48093-2566 | |
| (586) 216-9253 | |
| (586) 232-9127 |
| Full Name | International Therapy Solutions, Pllc |
|---|---|
| Speciality | Social Worker |
| Location | 11480 E. 13 Mile Rd, Warren, Michigan |
| Authorized Official Name and Position | Franka Arcangeli (LICENSED MASTER SOCIAL WORKER) |
| Authorized Official Contact | 5862169253 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| International Therapy Solutions, Pllc 11480 E. 13 Mile Rd Warren MI 48093-2566 Ph: (586) 216-9253 | International Therapy Solutions, Pllc 11480 E. 13 Mile Rd Warren MI 48093-2566 Ph: (586) 216-9253 |
| NPI Number | 1093254120 |
|---|---|
| Provider Enumeration Date | 02/22/2017 |
| Last Update Date | 05/25/2023 |
| Certification Date | 05/25/2023 |
| Medicare PECOS PAC ID | 9739463084 |
|---|---|
| Medicare Enrollment ID | O20170303002038 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093254120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 6801093974 (Michigan) | Primary |
| Provider Name | Iyantta S Howell |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1750545075 PECOS PAC ID: 1759608904 Enrollment ID: I20150812006379 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Franka Arcangeli |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114474251 PECOS PAC ID: 5890079164 Enrollment ID: I20170306000668 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Alexis N Lykins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154982346 PECOS PAC ID: 6507193612 Enrollment ID: I20210316002041 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Frances J Groce |
|---|---|
| Provider Type | Practitioner - Psychologist Billing Independently |
| Provider Identifiers | NPI Number: 1588871461 PECOS PAC ID: 9335526938 Enrollment ID: I20220520001065 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Stefana Bojescu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093457400 PECOS PAC ID: 6901285303 Enrollment ID: I20220615000578 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Sara L Neumann |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1689308330 PECOS PAC ID: 5698158277 Enrollment ID: I20220815001188 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Amanda L Ravel |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1538685821 PECOS PAC ID: 2961736400 Enrollment ID: I20220826000294 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Diana A Escamilla |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811448772 PECOS PAC ID: 9335524040 Enrollment ID: I20220916000711 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Mina T Blatt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932766557 PECOS PAC ID: 9133595416 Enrollment ID: I20221012002225 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Kristy Berchulc |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1720707755 PECOS PAC ID: 0345615357 Enrollment ID: I20230405000529 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Courtney L Monreal |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841814696 PECOS PAC ID: 7719352590 Enrollment ID: I20230410000171 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Breana M Lewis |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356924948 PECOS PAC ID: 7012376577 Enrollment ID: I20230701000258 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Gabriele M Schwarz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639544711 PECOS PAC ID: 0143689430 Enrollment ID: I20230705001582 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Prathima Mistry |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1902021405 PECOS PAC ID: 4587720826 Enrollment ID: I20230725002066 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
| Provider Name | Amanda K Makhzoum |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1932819802 PECOS PAC ID: 5799146536 Enrollment ID: I20230726003826 |
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
News Archive
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.
GPs could more accurately predict the likely progression of disease in patients with musculoskeletal conditions by asking them a simple set of generic questions during their very first consultation, new research funded by Arthritis Research UK has shown.
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
› Verified 6 days ago
Brighter Days Ahead Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 23905 Warner Ave, Warren, MI 48091 Phone: 586-823-6322 | |
Neurocognitive Center Of Michigan Group Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 28800 Ryan Rd, Suite 300, Warren, MI 48092 Phone: 586-582-0500 Fax: 586-620-8113 | |
Auburn Neurology Associates Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 27101 Schoenherr Ave, Ste 200, Warren, MI 48088 Phone: 734-459-7444 Fax: 734-459-7755 | |
New Oakland Child-adolescent And Family Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8150 E 13 Mile Rd, Warren, MI 48093 Phone: 586-825-9700 Fax: 586-825-9701 | |
Behavioral Therapists Billin Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4050 E 12 Mile Rd, Warren, MI 48092 Phone: 586-261-2166 Fax: 586-261-3628 | |
Comprehensive Counseling Center Pc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 11885 E 12 Mile Rd, Ste. 201a, Warren, MI 48093 Phone: 586-558-6000 Fax: 586-558-6679 |